Session Abstract – PMWC 2018 Silicon Valley
The PMWC 2018 Immunotherapy Showcase will take place on Tuesday, January 23 & Wednesday, January 24 and will provide a 15-minute time slot for selected immunotherapy companies to present their latest technologies and advancements to an audience of leading investors, potential clients, and partners. We will hear from companies building new cell-based immunotherapies, work in the growing area of cancer vaccines, that help understand the relevance of the tumor microenvironment, accelerate the patient selection process, or otherwise work towards overcoming to challenges related to therapeutic discovery.
Confirmed Presenting Companies:
The PMWC 2018 Immunotherapy Showcase will take place on Tuesday, January 23 & Wednesday, January 24 and will provide a 15-minute time slot for selected immunotherapy companies to present their latest technologies and advancements to an audience of leading investors, potential clients, and partners. We will hear from companies building new cell-based immunotherapies, work in the growing area of cancer vaccines, that help understand the relevance of the tumor microenvironment, accelerate the patient selection process, or otherwise work towards overcoming to challenges related to therapeutic discovery. Confirmed Presenting Companies:
- Abpro
- Adaptimmune
- Affimed
- Atreca
- Bavarian Nordic
- BeiGene
- Bellicum Pharmaceuticals
- BioEclipse Therapeutics
- Caris Life Sciences
- Celyad
- Colby Pharmaceutical Company
- Compugen
- Five Prime Therapeutics
- Fred Hutchinson Cancer Research
- Genocea Biosciences
- Gritstone
- HealthTell, Inc.
- Idera Pharmaceuticals
- Immix Biopharma
- Immune Design
- Immune System Key
- ImmunGene
- Imperial Healthcare NHS Trust
- Incyte
- Kite Pharma
- Massachusetts General Hospital
- Medigene AG
- Mitra Biotech
- Nektar Therapeutics
- OncoResponse
- Personal Genome Diagnostics
- Personalis
- Precision Oncology
- Stanford University
- UCSC
- Xcell Biosciences
- Xyphos
Session Chair Profile
Ph.D., Vice President, Cancer Immunology, Genentech
Biography
Ira Mellman came to Genentech in the Spring of 2007 as Vice President of Research Oncology, after more than 20 years as a faculty member at the Yale University School of Medicine, where he was chair of his department (Cell Biology), a member of the Ludwig Institute for Cancer Research, scientific director of the Yale Cancer Center, and Sterling Professor of Cell Biology and Immunobiology. Dr. Mellman has a BA from Oberlin College & Conservatory and a PhD in Genetics from Yale. He was a Postdoctoral Fellow at the Rockefeller University with Ralph Steinman, who received the Nobel Prize for the discovery of dendritic cells. His laboratory is known not only for advances in fundamental cell biology particularly in the area of membrane traffic (including the discovery of “endosomes”) but also for applying these insights to understanding the cellular basis of the immune response, especially dendritic cell function. He was also the founder of CGI Pharma, which was recently purchased by Gilead. Ira ran all of oncology research at Genentech until the end of 2013 when he decided to concentrate his efforts on the rapidly developing area of cancer immunotherapy and became Vice President of Cancer Immunology. Ira is a member of the National Academy of Sciences, American Academy of Arts & Sciences, the European Molecular Biology Organization, and the former Editor in Chief of the Journal of Cell Biology. He has also served on the editorial boards of Cell, the Journal of Experimental Medicine, EMBO Journal, among others. He also serves on the boards of the Society for the Immunotherapy of Cancer, the American Society for Cell Biology, and the Cancer Research Institute. He remains a frustrated composer and songwriter, and has recorded two CDs in the little-known genre of “bio-rock”.
